NUAK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL270735	0.56	3/20
Nintedanib (SCHEMBL431006)	0.51	3/20
Nintedanib (SCHEMBL431007)	0.51	3/20
SCHEMBL436539	0.47	3/20
SCHEMBL93699	1.00	2/20
SCHEMBL619716	0.95	2/20
SCHEMBL147331	0.91	2/20
SCHEMBL141930	0.90	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL93510	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL616960	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL146263	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20
SCHEMBL144281	0.68	2/20
SCHEMBL141372	0.68	2/20
SCHEMBL145902	0.67	2/20

Clinical trials — most relevant to NUAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a NUAK1 binder may also engage these)

Protein	Name	Similarity
Q641K5	—	1.000	Q641K5 →
Q66HE5	—	0.997	Q66HE5 →
Q68UT7	—	0.996	Q68UT7 →
Q63553	—	0.996	Q63553 →
Q8BZN4	—	0.995	Q8BZN4 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.995	landscape →
A7MBB4	—	0.993	A7MBB4 →
Q8VDU5	—	0.993	Q8VDU5 →
NUAK2	NUAK family SNF1-like kinase 2	0.993	landscape →
Q3ULB5	—	0.992	Q3ULB5 →
Q811L6	—	0.992	Q811L6 →
D3ZML2	—	0.991	D3ZML2 →
Q5R7G9	—	0.991	Q5R7G9 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.991	landscape →
Q6P0Q8	—	0.991	Q6P0Q8 →
Q924U5	—	0.991	Q924U5 →
Q8RXT4	—	0.990	Q8RXT4 →
B1WAS2	—	0.990	B1WAS2 →
Q5TKR9	—	0.990	Q5TKR9 →
Q8BWQ5	—	0.990	Q8BWQ5 →
O88866	—	0.990	O88866 →
Q5R8Z4	—	0.990	Q5R8Z4 →
Q9JKY3	—	0.990	Q9JKY3 →
Q9R1L5	—	0.989	Q9R1L5 →
Q76I79	—	0.989	Q76I79 →
Q9Z1J2	—	0.989	Q9Z1J2 →
SNRK	SNF-related serine/threonine-protein kinase	0.989	landscape →
TESK2	Dual specificity testis-specific protein kinase 2	0.989	landscape →
Q60700	—	0.989	Q60700 →
Q8BZT2	—	0.989	Q8BZT2 →